|
| (4-chloro-2-methyl-5-oxo-1-phenyl-2,5-dihydro-1H-pyrazol-3-yl)methyl imidothiocarbamate |
|
Helicobacter |
Flagella |
Preclinical (in vivo) |
Suerbaum S, et al. 2022. mBio |
|
| (4-bromo-2-methyl-5-oxo-1-phenyl-2,5-dihydro-1H-pyrazol-3-yl)methyl imidothiocarbamate |
|
Helicobacter |
Flagella |
Preclinical (in vitro) |
Suerbaum S, et al. 2022. mBio |
|
| 1-{(E)-[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)imino]methyl}naphthalen-2-ol |
|
Pseudomonas
Yersinia |
TTSS (Type III secretion system)
TTSS (Type III secretion system) |
Preclinical (in vitro)
Preclinical (in vitro) |
Harmon DE, et al. 2010. Antimicrob Agents Chemother
|
|
| 5-methyl-2-phenyl-4-[(2,4,6-tribromophenyl)iminomethyl]-1H-pyrazole-3-thione |
|
Staphylococcus |
Others |
Preclinical (in vitro) |
Suree N, et al. 2009. Bioorg Med Chem |
|
| 5-methyl-4-{[(4-nitrophenyl)amino]methylene}-2-phenyl-2,4-dihydro-3H-pyrazole-3-thione |
|
Staphylococcus |
Others |
Preclinical (in vitro) |
Suree N, et al. 2009. Bioorg Med Chem |
|
| 3-(4-CHLOROPHENYL)-N-[2-(DIMETHYLAMINO)ETHYL]-5-METHYL-2-(TRIFLUOROMETHYL)PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE |
|
Vibrio |
Stress survival |
Preclinical (in vitro) |
Stanbery L, et al. 2017. Drug Des Devel Ther |
|
| 2-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)iminoindene-1,3-dione |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Hu X, et al. 2013. Bioorg Med Chem Lett |
|
| 5-[3'-(4-methylphenyl)-1'-phenyl-5-(2-thienyl)-3,4-dihydro-1'H,2H-3,4'-bipyrazol-2-yl]-5-oxopentanoic acid |
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Pan NJ, et al. 2009. Antimicrob Agents Chemother |
|
| | | |
| | | |
| | | |
| | | |
| | | |
